Evidence map›Paper›PMID 26454858›Full record

Observational studyJournal of nephrology2016

Comparison of two different vitamin D supplementation regimens with oral calcifediol in kidney transplant patients.

Xoana Barros, Nestor Y Rodríguez, David Fuster, Lida Rodas, Nuria Esforzado, Alberto Mazza, Domenico Rubello, Francisco Campos, Andrés Tapias, José-Vicente Torregrosa

Abstract readComparative StudyObservational Study
PubMed Publisher
In one paragraph

Observational study in Journal of nephrology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.3field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Observational
  5. Review
  6. Review
  7. Review
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 2 countries.

Xoana BarrosNephrology and Kidney Transplant Department, Hospital Clinic, Villarroel, 170, 08036, Barcelona, Spain.
Nestor Y RodríguezNephrology and Kidney Transplant Department, Hospital Clinic, Villarroel, 170, 08036, Barcelona, Spain.
David FusterNuclear Medicine Department, Hospital Clinic, Barcelona, Spain.
Lida RodasNephrology and Kidney Transplant Department, Hospital Clinic, Villarroel, 170, 08036, Barcelona, Spain.
Nuria EsforzadoNephrology and Kidney Transplant Department, Hospital Clinic, Villarroel, 170, 08036, Barcelona, Spain.
Alberto MazzaInternal Medicine Department, Santa Maria della Misericordia Hospital, Rovigo, Italy. mazza.alberto@azisanrovigo.it.
Domenico RubelloNuclear Medicine Department, Santa Maria della Misericordia Hospital, Rovigo, Italy.
Francisco CamposNuclear Medicine Department, Hospital Clinic, Barcelona, Spain.
Andrés TapiasNuclear Medicine Department, Hospital Clinic, Barcelona, Spain.
José-Vicente TorregrosaNephrology and Kidney Transplant Department, Hospital Clinic, Villarroel, 170, 08036, Barcelona, Spain.
Hospital Clínic de Barcelona · ESOspedale Santa Maria della Misericordia di Rovigo · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionVitamin D deficiency is prevalent in kidney transplant recipients (KTR) and recommendations on how to replenish vitamin D deposits are scarce.

aimTo evaluate, in KTR, the safety and efficacy of calcifediol in two different vitamin D supplementation regimens, in order to assess the most suitable dose. PATIENTS AND

methodsProspective observational study with two calcifediol supplementation regimens randomly prescribed by clinicians in liquid form, at 266 mcg doses, monthly or biweekly. We analyzed 168 KTR with a functioning allograft for more than 6 months. Patients receiving other vitamin D forms, calcimimetics or bisphosphonates were excluded. Before calcifediol initiation (pre-treatment levels) and after at least 3 months of treatment (post-treatment levels), we measured serum levels of 25-OH vitamin D (25(OH)D), parathyroid hormone (PTH), alkaline phosphatase (ALP), calcium (sCa), phosphate (sPO4) and creatinine (sCreat).

resultsIn the monthly group (n = 72), 25(OH)D levels increased from 14 ng/ml [interquartile range, IQR 9-22] at baseline to 31 [20-38] (p = 0.000), PTH decreased from 124 pg/ml [87-172] to 114 [78-163] (p = 0.006), while sCa and sPO4 remained stable. In the biweekly group (n = 96), 25(OH)D increased from 14 ng/ml [9-20] at baseline to 39 [28-52] (p = 0), PTH decreased from 141 pg/ml [95-221] to 112 [90-180] (p = 0.000), sCa remained stable and sPO4 increased from 3.3 ± 0.6 mg/dl to 3.5 ± 0.6 (p = 0.003). Renal function remained stable in both groups.

conclusionVitamin D reposition with oral calcifediol, in a biweekly or monthly regimen, is safe and effective in improving 25(OH)D blood levels and in decreasing PTH in kidney transplant recipients.

Indexed as

Dietary SupplementsKidney TransplantationTransplant RecipientsAdministration, OralAdultAgedBiomarkersCalcifediolDrug Administration ScheduleFemaleHumansMaleMiddle AgedParathyroid HormoneProspective StudiesTime Factors25-hydroxyvitamin DBiomarkersCalcifediolParathyroid HormonePTH protein, humanVitamin DVitaminsCalcifediolKidney transplantParathyroid hormoneVitamin D

Identifiers

PMID26454858
OpenAlexW2212665234

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.